New real-world data confirms that the diabetes and weight-loss medications Ozempic (semaglutide) and Mounjaro (tirzepatide) offer powerful cardiovascular protection. A study found these drugs significantly reduce the risk of major events like strokes and heart attacks in patients with Type 2 diabetes, demonstrating benefits beyond simple blood sugar control. This finding marks a major shift in diabetes care.
